Study in mice links vasopressin shortfall to social deficits tied to Shank3 mutation, points to targeted-receptor therapy

Researchers in Spain reported that a deficit in the brain hormone vasopressin may underlie social deficits produced by mutations in the Shank3 gene in a mouse model, and that selectively targeting vasopressin receptor pathways restored sociability without increasing aggression. The experiments, described in a study published in Nature Communications in July, identify a potential mechanistic link between a genetic mutation long associated with autism and specific changes in a neural signaling pathway that regulates social behavior.

Investigators at the Institute of Neurosciences at Universidad Miguel Hernández de Elche genetically modified mice to carry a mutation in Shank3, a gene involved in organizing synaptic connections. Shank3 mutations have been implicated in a range of neurodevelopmental and neurocognitive conditions, including forms of autism. The modified mice underwent behavioral testing that included free roaming, one‑on‑one social interactions and exposure to an unfamiliar mouse. Compared with control animals, Shank3‑mutant mice showed reduced exploratory and social behaviors.

Neuroanatomical and molecular analyses revealed that the mutant mice had fewer neurons that release vasopressin and reduced vasopressin availability in the lateral septum, a brain region involved in regulating social behavior, anxiety and fear. Vasopressin binds to multiple receptor subtypes; the research team focused on two pathways they say mediate distinct effects — one associated with interpreting social cues and another linked to aggression. In the Shank3 model, insufficient vasopressin reaching the lateral septum corresponded with both reduced sociability and lowered aggression, the latter of which the authors note can be adaptive in territorial behavior in mice.

To separate these effects, the researchers manipulated the receptor pathways independently. Pharmacological activation of the AVPR1a receptor, which the team associates with sociability, improved social interactions in the mutant mice without producing a concomitant rise in aggressive behavior. The investigators have filed a patent application related to developing drugs that selectively activate AVPR1a to enhance social behavior while avoiding activation of aggression‑linked pathways.

"We managed to improve sociability without increasing aggression, which is fundamental if we are thinking about a future treatment," said Dr. Félix Leroy, lead author and researcher at the institute. The paper also reports that the vasopressin system is more prominent in males in this model, a finding the authors suggest may contribute to sex differences in autism diagnosis rates. The U.S. Centers for Disease Control and Prevention reports a higher prevalence of diagnosed autism among boys than girls; the study authors note sex differences in vasopressin signaling could be one factor warranting further study.

The researchers cautioned that the findings are from an animal model and that translation to humans is not established. The study’s approach isolates a specific biochemical pathway downstream of a known genetic lesion, providing a mechanistic hypothesis rather than a confirmed human treatment. The authors and external experts emphasized the need for additional preclinical work and careful clinical evaluation before considering therapeutic trials in people.

Genetic studies estimate a substantial heritable component to autism risk, with a range of published estimates; some research attributes 40 to 80 percent of risk to genetic factors and suggests single‑gene mutations account for a portion of cases. Current drugs that alter vasopressin signaling, such as tolvaptan and conivaptan, are used to manage disorders of sodium balance and kidney function and act systemically; the selective receptor activation proposed by the Spanish team would aim for a different, more targeted central nervous system effect.

The study supplies a mechanistic bridge from a specific autism‑linked genetic mutation to altered social behavior in mice and identifies receptor‑selective modulation of vasopressin signaling as a candidate approach to improve social deficits. Researchers noted that any translation to human diagnosis or treatment would require rigorous validation, attention to sex differences, and development of compounds capable of precisely engaging the intended neural pathways without off‑target effects.